Running head: BENEFITS OF THE COVID-19 VACCINE 1

Rhetorical Analysis of Sources of the Benefits of the Covid-19 Vaccine

Student’s Name

Institutional Affiliation
BENEFITS OF THE COVID-19 VACCINE 2

Rhetorical Analysis of Sources of the Benefits of the Covid-19 Vaccine

Regulatory and medical decisions are primarily based on benefit-related predictions. As a

result, developing a coronavirus disease prevention vaccine for 2019 (COVID-19) is a global

priority. It's essential to identify potential stumbling blocks and stakeholders. If protection

against SARS–Coronavirus 2 (SARS-CoV-2) is caused by broader use of an effective vaccine or

repeated waves of infection in the coming years before sixty percent to seventy percent of people

experience symptoms, the pandemic potential spread viruses to higher levels of population

immunity (herd) exists. Repeated epidemics of SARS-CoV-2 will result in unsustainable deaths,

severe economic disruption, and significant lifestyle changes as humans develop immunity to the

virus. As a result, developing an effective vaccine is hugely beneficial, mainly if used in time to

avoid future epidemics.

Barton F. Haynes answers the core issue of why the Victoria Admitted Episode Dataset

(VAED) is listed as a potential COVID19 vaccine in his blog post, Covid-19 safety vaccine

prospects. This question should be asked of all current vaccine applicants, regardless of the

exceptional circumstances (Haynes, 2020). COVID-19 vaccines will be made more widely

available if regulators determine that they are safe and efficient after conducting feasibility trials

of up to 30 000 people. Even though the vaccine's safety and effectiveness are currently being

assessed in the United States, the European Union, and other parts of the world, following the

most recent regulatory guidelines, have contributed to an increase in the capacity to produce and

deliver millions of vaccine doses to combat the pandemic. Besides, a large number of people

must be vaccinated before long-term monitoring can be undertaken.

Furthermore, COVID 19 vaccines can be made available to people over 65, who have

never been exposed to the disease, even though the bulk of data on vaccine reactions in this age
BENEFITS OF THE COVID-19 VACCINE 3

group comes from booster vaccinations. COVID-19, on the other hand, is at phase 3 vaccine trial

that looks at how people's immune responses change as they age. Based on current knowledge,

conducting randomized phase 3 placebo-controlled trials is the most effective way to determine

if a COVID 19 vaccine candidate poses a VAED risk. The prevalence of VAEDs, the period

following vaccination during which VAEDs can occur, and the distinction between VAEDs and

natural diseases of similar severity all play a role in detecting VAEDs in clinical trials. At this

time, there is no way to tell the difference between VAED and natural COVID-19 using clinical

markers. From the conclusion, they suggested that the vaccine will have potential benefits rather

than a risk of more severe disease.

Ronald N. Kostoff, in the article “COVID19 vaccine protection,” far outweigh the

project's costs. Potential costs and advantages may be estimated with a high, moderate, or low

degree of certainty. As a result, the costs and benefits must be adjusted to account for the

forecasts' degree of uncertainty. The long- and medium-term health effects of the COVID-19

vaccine are demonstrated in this study using vaccine rates. It is a dangerous proposition to invest

in a vaccine with uncertain long-term costs. A significant benefit should be predicted in the

future to justify the trade-off (Kostoff, 2020). The cost-benefit analysis of a vaccine-like

COVID-19 would be different for groups of varying degrees of disease susceptibility. Vaccines

may be split into two target categories: sicker and the general public, to make vaccination

compliance easier. The immune systems of the elderly and those in the most vulnerable

population groups, especially those with multiple comorbidities, are compromised. The elderly

population is much higher than the general population, despite accounting for just a tiny

percentage of the total population. There are few, if any, signs in the general population when
BENEFITS OF THE COVID-19 VACCINE 4

SARS-CoV-2 infects them. This population segmentation corresponded to the pandemics of

influenza and SARS in 2002 and 2003.

Both of these variants will be evaluated separately in the vaccine trade-off analysis.

During the holiday season, they place a premium on the welfare of the most vulnerable people.

The short- and long-term consequences may be less severe (though the medium- and long-term

consequences for the few younger members of this ethnic group with a significantly impaired

immune system may be significant) (although for the few younger members of this demographic

population with highly compromised immune systems, the mid-and long-term adverse effects

would not be negligible). It's debatable whether a vaccine is appropriate for the most vulnerable

people because of the minor side effects (most of the population). Any vaccine that has not been

adequately tested will have serious long-term health effects for those who are most vulnerable.

In the short term, a vaccine that is effective for all populations can be justified (though

risky) for the most vulnerable population. For the remaining populations, however, it is difficult

to see how such vaccination might be justified. What are the most up-to-date predictions for the

efficacy of a short-term vaccine? The study was recent and consistent (41,42), with publicly

available test results for a widely available COVID-19 vaccine that caused moderate to severe

harm in the most vulnerable elderly populations. Furthermore, the vaccine's short-term efficacy

for the least vulnerable population, let alone the most vulnerable, which is the vaccine's most

justifiable target, has yet to be determined.

SARS-CoV-2 infection and its related manifestations of serious diseases pose a threat to

children of all ages. Even though most COVID-19 patients have no or minor symptoms, 18.4

children aged 0 to 4 years and 10.6 children aged 5 to 17 years need hospitalization, with one-

third of these needing intensive care. Patients in their late adolescence and children are the most
BENEFITS OF THE COVID-19 VACCINE 5

likely to need hospitalization. Medical uncertainty, immunosuppressive conditions, and obesity

are all factors that raise the risk of being admitted to the intensive care unit; even though current

medical conditions clearly increase a child's likelihood of contracting a significant disease,

previously healthy children are also at risk of developing severe COVID-19 and inflammatory

multi-system syndrome (MIS-C). Intensive MIS-C can cause myocardial instability, shock, and

respiratory failure. Extreme COVID-19 symptoms and MIS-C have a disproportionate impact on

black and Hispanic white infants, just as adults do. As a result, the SARS-CoV-2 vaccine, like

other widely used pediatric vaccines, may reduce health inequalities among children of color and

ethnic minorities.

In addition to the direct health benefits of active immunity against SARS-CoV-2, a safe

and efficient pediatric vaccine will significantly reduce the adverse social effects of COVID-19

on infants. After the COVID-19 pandemic was declared in March 2020, over 57 million students

in all 50 states of the United States of America were forced to drop out of school. School

disruptions, health implications for children who depend on federally subsidized food,

inequalities in childcare and supervision, and economic consequences for families affected by

job loss are just some of the consequences of such unprecedented school closures. Children's

COVID-19 vaccinations will also help rebuild other intangible relationships that benefit children,

such as extracurricular sports. Concerns about the long-term effects of childhood vaccinations,

such as protective immunity levels and the vaccine's ability to avoid infection, transmission, and

symptomatic disease, are also valid. Nonhuman primate studies have shown that vaccination

against SARS-CoV-2 not only prevents infection but also reduces viral load in nasopharyngeal

and Bronchoalveolar lavage samples, potentially decreasing transmission. These questions will

be answered in pediatric COVID-19 vaccine clinical trials by assessing vaccine dosage,

BENEFITS OF THE COVID-19 VACCINE 6

immunity, reactogenicity, and immunogenicity in infants. Therefore, from Ronald N. Kolthoff

perspective, the vaccine to some extent will try to return the world to its normal situation.

Overall, it is evident from the discussion above that many people and states are

undecided on whether to apply the COVID19 vaccines to their citizens and which portion of the

population to receive the vaccine first. This is due to the circulating stereotypes surrounding the

safety of the vaccine. Many scholarly works have criticized the fast production of the vaccines

and question whether the vaccine was already manufactured even before the epidemic.

Moreover, there has been casing of side effects associated with the use of these vaccines and

therefore it is not well known if there are more dire health concerns regarding the same. To

understand this vaccine will take time.

BENEFITS OF THE COVID-19 VACCINE 7

References

Barton F. Haynes, M. (2020). A new vaccine to battle Covid-19. Duke University School of

Medicine.

Ronald N. Kostoff, 1. M. (2020). COVID-19 vaccine safety. International Journal of Molecular

Medicine